Management of Inflammatory Bowel Disease

Stephanie Chandra, Marcellus Simadibrata

Research output: Contribution to journalArticlepeer-review


Inflammatory bowel disease (IBD) is an inflammatory disease, which involves the digestive tract with still unknown definite etiology. IBD cases are frequently underdiagnosed or even overdiagnosed. Delay in diagnosis often happen due to the unspecific intermittent symptoms. Principally, treatment of IBD is targeted to acute episodes and maintenance of therapy during remission phase. First line therapy drugs include 5-acetil salicylic acid (5-ASA) and corticosteroids are systemic and topical. If failed, then second line therapy, which has immunosuppressive characteristic, is given such as: 6-mercaptopurine, azathioprine, cyclosporine, methotrexate, and anti-TNF (infliximab). Efforts to prevent recurrent inflammation in IBD are to maintain the remission phase as long as possible. Surgery management may be considered if conservative of pharmacological treatment fails or complication happens.
Original languageEnglish
JournalThe Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy
Publication statusPublished - 2014


Dive into the research topics of 'Management of Inflammatory Bowel Disease'. Together they form a unique fingerprint.

Cite this